CA2539801A1 - Preparation therapeutiques - Google Patents

Preparation therapeutiques Download PDF

Info

Publication number
CA2539801A1
CA2539801A1 CA002539801A CA2539801A CA2539801A1 CA 2539801 A1 CA2539801 A1 CA 2539801A1 CA 002539801 A CA002539801 A CA 002539801A CA 2539801 A CA2539801 A CA 2539801A CA 2539801 A1 CA2539801 A1 CA 2539801A1
Authority
CA
Canada
Prior art keywords
epothilone
cyclodextrin
dehydroepothilone
appl
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002539801A
Other languages
English (en)
Inventor
Michael Sherrill
Robert G. Johnson, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences, Inc.
Michael Sherrill
Robert G. Johnson, Jr.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/683,952 external-priority patent/US7091193B2/en
Application filed by Kosan Biosciences, Inc., Michael Sherrill, Robert G. Johnson, Jr. filed Critical Kosan Biosciences, Inc.
Publication of CA2539801A1 publication Critical patent/CA2539801A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
CA002539801A 2003-10-09 2004-10-08 Preparation therapeutiques Abandoned CA2539801A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US03/032055 2003-10-09
US10/683,952 2003-10-09
US10/683,952 US7091193B2 (en) 2002-10-09 2003-10-09 Therapeutic formulations
PCT/US2003/032055 WO2004032866A2 (fr) 2002-10-09 2003-10-09 Preparations therapeutiques
PCT/US2004/033339 WO2005034964A1 (fr) 2003-10-09 2004-10-08 Preparation therapeutiques

Publications (1)

Publication Number Publication Date
CA2539801A1 true CA2539801A1 (fr) 2005-04-21

Family

ID=34437084

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002539801A Abandoned CA2539801A1 (fr) 2003-10-09 2004-10-08 Preparation therapeutiques

Country Status (4)

Country Link
EP (1) EP1670487A4 (fr)
KR (1) KR20060122819A (fr)
CA (1) CA2539801A1 (fr)
WO (1) WO2005034964A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674098A1 (fr) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Formulations parenterales stables et tolérables des substances de haut réactivité ayant une solubilité basse ou inexistante dans l'eau

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125921A (en) * 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
EP1767535B1 (fr) * 2002-08-23 2009-12-02 Sloan-Kettering Institute For Cancer Research Synthèse d'épothilones, intermédiaires, analogues et leurs utilisations
JP2006504743A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
KR100966667B1 (ko) * 2002-11-07 2010-06-29 코산 바이오사이언시즈, 인코포레이티드 트랜스-9,10-디히드로에포틸론 ｃ 및 ｄ, 그것의 유사체 및그것의 제조 방법

Also Published As

Publication number Publication date
EP1670487A1 (fr) 2006-06-21
WO2005034964A1 (fr) 2005-04-21
KR20060122819A (ko) 2006-11-30
EP1670487A4 (fr) 2008-05-21

Similar Documents

Publication Publication Date Title
US7091193B2 (en) Therapeutic formulations
Ma et al. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy
Kuppens Current state of the art of new tubulin inhibitors in the clinic
US20040167097A1 (en) EPO D + 5-FU/gemcitabine
JP4644364B2 (ja) エポシロン組成物
KR20120104173A (ko) 치료제의 미셀 캡슐화
KR20100057007A (ko) 치료제의 마이셀 캡슐화
CN102292079B (zh) 包含头孢洛林的组合物和治疗方法
US8945627B2 (en) Micelles for the solubilization of gossypol
EP1492529A1 (fr) Administration d'epothilones par voie orale
US20050148543A1 (en) Therapeutic formulations
CA2539801A1 (fr) Preparation therapeutiques
EP1604660B1 (fr) Composition medicinale pour traiter une infection due au staphylococcus aureus resistant aux medicaments
KR20090040299A (ko) 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물
EA016410B1 (ru) Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
US20050215604A1 (en) Combination therapies with epothilones and carboplatin
CN116350632A (zh) 头孢类抗生素作为制备靶向性抗癌药物或辅助抗癌保健品中的应用

Legal Events

Date Code Title Description
FZDE Discontinued